Oncology News Central Peer-Spectives

15:05

How Are Oncologists Managing Amivantamab Plus...

Oncology News Central Peer-Spectives ·

2026/10/02

Recording live at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, Estelamari Rodriguez, MD, MPH, from the Sylvester Comprehensive Cancer Center at the University of Miami, speaks with Wade Iams, MD, from Tennessee Oncology in Nashville, and Luis Raez, MD, from Memorial Cancer Institute in Miami, Forida, about selecting first-line combination therapy and managing amivantamab plus lazertinib in clinical practice.

en

14:28

Who Still Needs Monotherapy in EGFR- Mutant NSCLC

Oncology News Central Peer-Spectives ·

2026/09/24

At WCLC 2026, three thoracic oncologists discuss first-line combinations, toxicity management, and subcutaneous amivantamab.

en

16:01

Is It Time for a New Type of Cancer Physician?

Oncology News Central Peer-Spectives ·

2026/08/21

The dramatic increase in cancer survivorship is introducing questions about the ability of physicians to meet patient needs. “Maybe we need to have a survivor cancer patient see a survivorship physician,” Robert Figlin, MD, discusses with Sunita Puri, MD.

en

13:03

What the “Tsunami” of Cancer Survivors Means for...

Oncology News Central Peer-Spectives ·

2026/07/16

Advances in cancer treatments have led to a rising “tsunami” of survivors, which has introduced a new set of challenges for oncologists. Saro H. Armenian, DO, MPH, discusses what changes are needed across oncology with Robert A. Figlin, MD.

en

15:27

“Sobering” Takeaway From ASCO 2026: Concerns About...

Oncology News Central Peer-Spectives ·

2026/06/29

Amid the exciting advances at ASCO 2026, there came a “sobering moment” regarding the U.S.’s role as a cancer clinical trial leader, says Robert A. Winn, MD. He discusses what this means for cancer centers going forward with Robert A. Figlin, MD.

en

15:03

“A Lot More Asymptomatic Cancer Out There”: Major...

Oncology News Central Peer-Spectives ·

2026/06/23

The prospective randomized NHS-Galleri multicancer early detection trial didn’t meet its primary endpoint, but it did uncover a lot more early-stage cancers than predicted. Eric Klein, MD, and Robert Figlin, MD, talk about what the data reveal about cancer biology and for screening programs.

en

13:59

“The Ever-Shifting and Chaotic” State of CLL Care:...

Oncology News Central Peer-Spectives ·

2026/06/23

Data presented at the 2026 American Society of Clinical Oncology Annual Meeting add to the “ever-shifting and chaotic space” that is CLL care, says Matthew Lunning, DO. He discusses how new findings are affecting practice with Robert A. Figlin, MD.

en

9:28

New Targeted Therapies Make Breast Cancer Treatment...

Oncology News Central Peer-Spectives ·

2026/04/21

“In breast cancer now, all of our treatment for hormone receptor–positive metastaticdisease is a bit of a moving target because of new therapies that are available,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women’s Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses the “ever-changing” landscape involving the PI3 kinase/AKT/mTOR pathway with Robert A. Figlin, MD, the Steven Spielberg Family Chair in

en

12:14

Advances in ESR1-Mutated Breast Cancer Care Lead to...

Oncology News Central Peer-Spectives ·

2026/04/17

As the management of patients with ESR1-mutated metastatic breast cancer evolves, various questions have emerged in clinical practice. “It's a complex situation,” explains Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers Program director at the City of Hope Comprehensive Cancer Center in Duarte, California. She discusses how recent advances have changed treatment decisions with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology

en

12:56

Second-Line Options in EGFR-Mutated NSCLC: What’s the...

Oncology News Central Peer-Spectives ·

2025/12/18

en

11:39

Big News From ESMO 2025 Changes Practice in Bladder...

Oncology News Central Peer-Spectives ·

2025/10/30

Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at the European Society of Medical Oncology Annual Congress. “Overall, this is going to change the standard of care for muscle-invasive bladder cancer,” says Amanda Nizam, MD, a genitourinary medical oncologist at the Cleveland Clinic Taussig Cancer Institute. She and Robert A. Figlin, MD, the interim director of Cedars-Sinai

en

16:47

Artificial Sweetener May Impair Cancer Immunotherapy,...

Oncology News Central Peer-Spectives ·

2025/09/22

The artificial sweetener sucralose may impair the efficacy of cancer immunotherapy, according to a recent study published in Science. Although further research is needed before these findings can be translated into actionable information for patients, the investigation highlights that “the science of nutrition in cancer is actually quite poor,” says senior author Diwakar Davar, MD, associate professor and clinical director of the melanoma and skin cancer program at the University of Pittsburgh

en

9:54

“Massive Advance” Changes the Chessboard in...

Oncology News Central Peer-Spectives ·

2025/09/16

New survival data from the FLAURA2 and MARIPOSA trials represent “a massive advance for our patients” in terms of frontline treatment for EGFR-mutated non-small cell lung cancer says Sandip P. Patel, MD, professor of medicine at the University of California San Diego. However, the findings have led to new questions about sequencing. “Just like in chess, when you make a move, you’re restricted in the moves that you can make afterward,” he explains to Robert A. Figlin, MD, the interim director of

en

11:29

Are Oral SERDs About to Transform Breast Cancer Care?

Oncology News Central Peer-Spectives ·

2025/07/15

The development of oral selective estrogen receptor degraders (SERDs) represents substantial progress for patients with metastatic breast cancer who have ESR1 mutations. “I’m extremely excited because they’re the most effective form of endocrine therapy today,” says Wassim Mchayleh, MD, MBA, the clinical program director of the breast cancer program at AdventHealth Cancer Institute and associate professor of medicine at the University of Central Florida in Orlando. He spoke with Robert A. Figlin,

en

10:37

Game-Changers and Paradigm Shifts: ASCO 2025 Data...

Oncology News Central Peer-Spectives ·

2025/07/14

From a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Tolaney broke down some of the top data at ASCO 2025 with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, California, and

en

09:29

Oncologist Faculty Burnout Caused by “Unrealistic”...

Oncology News Central Peer-Spectives ·

2025/07/08

“An increasingly unrealistic set of performance expectations” is putting a strain on oncologist faculty members, says Clifford Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO). He discussed the mounting challenges for academic cancer physicians and how ASCO is working to address them with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology. Dr. Hudis explained that academic oncologists are

en

12:23

After Years of Inactivity, “Dizzying” Changes Hit...

Oncology News Central Peer-Spectives ·

2025/07/07

“For the first 15 years of my career, we had nothing new” in bladder cancer care, said Jonathan E. Rosenberg, MD, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. Now, “the pace of change has been dizzying,” he told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology. Speaking at the 2025 American Society of Clinical Oncology Annual Meeting, Dr. Rosenberg

en

12:28

Practice Changing or “Practice Confounding”? Pivotal...

Oncology News Central Peer-Spectives ·

2025/07/03

Findings from the SERENA-6 trial, which examined switching therapies in patients with breast cancer ahead of disease progression, made headlines during the 2025 American Society of Clinical Oncology Annual Meeting. However, big questions remain. “I don’t know for sure if the approach is practice changing yet. I think the approach is practice confounding,” said Stephanie Graff, MD, director of breast oncology at Brown University Health Cancer Center in Providence, Rhode Island. Dr. Graff discussed

en

12:22

NCCN CEO Discusses Guideline Updates, Other Key...

Oncology News Central Peer-Spectives ·

2025/07/01

From digitizing its guidelines to potential embedding them in EMRs, the National Comprehensive Cancer Network (NCCN) is working to “make the workflow easier and better” for oncologists, Crystal S. Denlinger, MD, FACP, CEO of the NCCN, told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Denlinger broke down the organization’s

en

13:08

Former National Cancer Institute Director Discusses...

Oncology News Central Peer-Spectives ·

2025/06/24

“Is it time to do something big and different? That’s always a good question to ask,” said W. Kimryn Rathmell, MD, PhD, MMHC, the immediate former director of the National Cancer Institute (NCI) and the current CEO of The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. At the 2025 American Society of Clinical Oncology Annual Meeting, Dr. Rathmell spoke with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, and

en

All Episodes

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Short Science Fiction Collection

Vaqrious

Planetterrian Daily

Patrick · Nerra Network

Short Wave

NPR

La Science CQFD

France Culture